This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. The early-stage pipeline for amyotrophic lateral sclerosis ...
The MarketWatch News Department was not involved in the creation of this content. This funding was awarded through the ALS Association's Hoffman ALS Clinical Trial Awards Program, which aims to ...
Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for only two to five years after being diagnosed, according to the Centers for ...
LOS ANGELES, March 31, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to targeting cancer and autoimmune diseases through ...
A look at Amyotrophic Lateral Sclerosis (ALS), focusing on motor neuron degeneration, sporadic versus familial ...
ALS is a progressive disease, meaning it worsens over time. Although there is no cure for ALS, medications and therapies are available to help manage the symptoms, slow the disease course, and prolong ...
Pictured are nuclei of induced pluripotent stem cell (iPSC)-derived motor neurons stained for contrast. The nucleus on the left has been treated with DMSO (control) and appears mostly blue. The ...
This funding was awarded through the ALS Association's Hoffman ALS Clinical Trial Awards Program, which aims to accelerate the development of new ALS treatments ARLINGTON, Va., Dec. 4, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results